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Introduction: Patients with active rheumatoid arthritis who had failed at least one disease-modifying anti-
rheumatic drug (DMARD) were treated with adalimumab (ADA) in the ReAct study with the option to continue
treatment for 5 years in ReAlise. The purpose of this study was to evaluate the long-term safety and effectiveness of
ADA as prescribed from the first injection in ReAct to the last observation in ReAlise.
Methods: Patients received ADA alone or in combination with DMARDs according to usual clinical care practices.
Adverse events (AEs) were tabulated by five time windows after the first ADA injection. Effectiveness measures
included achievement of low disease activity (LDA), defined as Simplified Disease Activity Index (SDAI) ≤11, or
remission, (REM), defined as SDAI ≤3.3.
Results: Of the 6,610 ReAct patients, 3,435 (52%) continued in ReAlise. At baseline in ReAct, mean age was 54 years,
mean DAS28 was 6.0 and mean HAQ DI was 1.64. The mean treatment duration was 1,016 days, representing
18,272 patient-years (PYs) of ADA exposure. Overall incidence rates of serious AEs and serious infections were 13.8
and 2.8 events (E)/100 PYs, respectively. Serious AEs occurred most frequently in the first 6 months and deceased
thereafter. Standardised mortality ratio was 0.71 (95% CI 0.57 to 0.87) and standardised incidence ratio for malignancies
was 0.64 (95% CI 0.53 to 0.76). LDA was achieved by 50% and REM by 21% of patients at last observation.
Conclusions: Results of this large observational study of ADA in routine clinical practice were consistent with
controlled trials, with no new safety concerns during a follow-up of more than 5 years. Effectiveness of ADA was
maintained during long-term observation.
Trial registration: NCT00448383, NCT00234884Introduction
Patients with rheumatoid arthritis (RA) may not respond
to treatment with disease-modifying anti-rheumatic
drugs (DMARDs) alone [1-4]. In patients who have failed
DMARD therapy for RA, clinical studies have demon-
strated the effectiveness of drugs directed against tumour
necrosis factor (TNF) as monotherapy or when used in
combination with DMARDs [2,5-10]. Adalimumab (ADA)* Correspondence: gerd.burmester@charite.de
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reproduction in any medium, provided the oris a fully human anti-TNF monoclonal antibody for the
treatment of moderate to severe RA. Initial clinical trials
of ADA in patients with RA demonstrated a good safety
profile, with improvements in disease signs and symptoms
and functional ability, achievement of clinical remission
and inhibition of radiographic disease progression [2,3,7].
The Research in Active Rheumatoid Arthritis (ReAct)
phase 3b study was initiated in 2002 to assess the safety
and effectiveness of ADA in RA patients who had failed
treatment with at least one traditional DMARD [11,12].
ADA was well tolerated and effective, alone or with
DMARDs, in 6,610 patients with active RA over a meantral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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long-term safety and effectiveness of ADA in clinical prac-
tice settings over 5 years in patients who completed
ReAct, the REgistry of HUMIRA™ in RA: a Long-Term In-
vestigation of Safety and Efficacy (ReAlise) observational
follow-up study was conducted (NCT00234884). The pri-
mary objectives of this analysis include examination of ad-
verse events (AEs) and the temporal pattern of their
occurrence and maintenance of response through 5 years
of ADA treatment (i.e., from the first injection received in
ReAct through the last observation in ReAlise).
Methods
Study design
ReAct was a 12-week, open-label multicentre study with
an optional extension phase until ADA became commer-
cially available. Methodology and results have been pub-
lished [11]. Briefly, ADA was administered to 6,610
patients with active RA (defined as 28-joint Disease Activ-
ity Score (DAS28) based on erythrocyte sedimentation rate
(ESR) ≥3.2 and an unsatisfactory response to at least one
synthetic DMARD). Patients also could have received prior
TNF antagonist therapy with infliximab and/or etanercept
if treatment was stopped 2 months before inclusion in
ReAct. Patients were allowed to continue treatment
with DMARDs, corticosteroids and non-steroidal anti-
inflammatory drugs (NSAIDs). Subsequently, patients could
enter ReAlise, a multicentre (10 European countries and
Australia), 5-year, uncontrolled observational study of
ADA in patients with long-standing, severe RA. Patients
were treated in accordance with physicians’ usual clinical
care practices and local marketing authorisation require-
ments for commercially available ADA. ReAlise was con-
ducted as a commitment to the European Medicines
Agency (EMEA) and in accordance with the Declaration
of Helsinki and applicable local regulations; each site’s in-
stitutional review board or independent ethics committee
approved the protocol (Additional file 1 and Additional
file 2 for ReAlise and ReAct, respectively), and all patients
provided written informed consent.
Patients
Patients aged ≥18 years were eligible for ReAlise if they
were in good health (per physician’s discretion) with a re-
cent stable medical history, receiving ongoing ADA treat-
ment, completed ≥3 months of the ReAct study, and were
prescribed ADA. Patients could enroll in ReAlise within
12 months of completing ReAct. Patients continued taking
concomitant medications, including DMARDs and cor-
ticosteroids, per usual care. Assessments were made at
weeks 2, 6 and 12, and every 8 weeks thereafter in ReAct,
every 3 months during the patients’ first year in ReAlise
and every 6 months thereafter until the last observation in
ReAlise.Assessments
This analysis includes clinical assessments of safety and ef-
fectiveness made at 0.5, 1, 3 and 5 years and the last visit
after the first ADA injection in ReAct. AEs were collected
throughout ReAct and ReAlise and for 3 months after the
last visit in ReAlise. There was no systematic collection of
AEs during the interval between the last assessment in
ReAct and enrolment in ReAlise. AEs were tabulated using
five time windows (≤0.5, 0.5 to 1, >1 to 3, >3 to 5 and >5
years) beginning after the first injection of ADA in ReAct.
Standardised mortality rates (SMRs) and standardised in-
cidence rates (SIRs) for malignancies were calculated for
all patients, for all completed treatment periods.
Clinical effectiveness was assessed by the following mea-
sures: American College of Rheumatology improvements
of 20% (ACR20), 50% (ACR50) and 70% (ACR70) [13];
European League Against Rheumatism (EULAR) categor-
ical responses of moderate and good [14]; DAS28 (ESR) in-
cluding individual components: swollen and tender joint
counts (SJC, TJC), patient global assessment (PtGA), and
ESR; low disease activity (LDA) and remission (REM) were
assessed using the Simplified Disease Activity Index (SDAI)
scores of ≤11 or ≤3.3, respectively [15]. Physical function-
ing was measured using the Health Assessment Question-
naire Disability Index (HAQ DI). Data were analysed for
mean HAQ DI scores, the percentage of patients with min-
imal important difference ≥0.22 and the percentage of
patients with normal function, defined as HAQ DI ≤0.5.Statistical analysis
Data were integrated from ReAct and ReAlise to evalu-
ate long-term ADA treatment. Safety and effectiveness
analyses were performed on the intention-to-treat (ITT)
population and included all patients who had at least
one ADA injection in ReAct. AEs were reported as
events (E) and E per 100 patient-years (PYs) for all
treated patients. For SMRs, study results were compared
against age- and sex-matched data from the World
Health Organization for each country in which the study
was conducted [16]. SIRs for malignancies were deter-
mined by comparing study results with the National
Cancer Institute (NCI) Surveillance, Epidemiology and
End Results (SEER) database for all malignancies and
lymphoma [17].
To examine the effect of different therapies on the in-
cidence of AEs, subgroup analyses were conducted for
patients receiving ADA monotherapy (defined as no
concomitant DMARD irrespective of combination with
corticosteroids or NSAIDs) versus combination therapy
of ADA with at least one DMARD. Patients also were
stratified by use of corticosteroids and prior use of TNF
antagonists (infliximab or etanercept) versus those who
had not used these medications.
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clinical effectiveness measures with continuous data (for ex-
ample, DAS28) using observed values. Categorical data (for
example, ACR, EULAR responses) were summarised with
absolute and relative frequencies using observed values.
Results
Patients
Of the 6,610 patients in ReAct, 3,435 (52%) opted to
continue ADA, as prescribed by their physician, in ReAl-
ise (Figure 1). Of the 3,435 patients who continued in
ReAlise, 1,805 (52.5%) completed the long-term study,
receiving 5 years or more of ADA. Primary reasons for
discontinuation in ReAlise were loss of efficacy (n = 557,
16.2%) or AEs (n = 429, 12.5%). Withdrawals were gen-
erally evenly distributed across time intervals, without
obvious clusters of withdrawals occurring for specific
reasons. AEs led to study withdrawal in approximately
2.5% of patients during the first 6 months and from 6 to
12 months and decreased to 1 to 22% during subsequent
6-month intervals through 60 months. Lack of efficacy
was cited as a reason for study withdrawal in 2 to 3% of
patients for all 6-month intervals.
Patient demographics and baseline clinical characteris-
tics are shown in Table 1. Moderate to severe disease ac-
tivity and functional impairment are demonstrated byEnroled in ReAct 
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Figure 1 Patient disposition. *ReAct was followed by ReAlise when ADA
further observed for safety and effectiveness over 5 years or more. †Discon
ReAlise study. ADA, adalimumab; ReAct, the Research in Active Rheumatoid
Long-Term Investigation of Safety and Efficacy observational follow-up studmean DAS28 (ESR) of 6.0 and mean HAQ DI score of
1.64. Before entry into ReAct, 97% of patients had taken
one or more DMARD. The percentages of patients who
had received methotrexate, leflunomide, antimalarials
(chloroquine or hydroxychloroquine), and sulfasalazine
were 89%, 42%, 42%, and 39%, respectively [11]. Etaner-
cept and/or infliximab were previously prescribed for
899 (13.6%) patients [12]. Reasons for discontinuing
TNF antagonists before ReAct were loss of response
(38% (327/870)), no primary response (22% (195/870))
and intolerance (22% (190/870)) [12]. At baseline of
ReAct, 74% (4,879/6,610) of patients were taking at least
one DMARD and 71% (4,708/6,610) were taking cortico-
steroids [11]. At first visit in ReAlise, most patients
(62%) were taking only one DMARD, and the most com-
mon agents were methotrexate (58%), leflunomide (13%),
antimalarials (8%) and sulfasalazine (6%). ADA was ad-
ministered as monotherapy for 26% of patients. Aside
from DMARDs, corticosteroids were the most frequently
administered concomitant medications. Of 3,175 patients
who completed ReAct but did not continue in ReAlise,
demographics and baseline clinical characteristics were
similar to the population that continued in ReAlise (data
not shown).
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and median treatment durations were 1,016 (895) andcontinued (n=1,630; 47.5%)†
s of efficacy (n=557; 16.2%)
erse events (n=429; 12.5%)
th (n=36; 1.0%)
t to follow-up (n=291; 8.5%)
hdrew consent (n=154; 4.5%)
er (n=254; 7.4%)
ccurred over time 
Act completion
pletions per year †
year, n=2,926
years, n=2,547
years, n=2,243
years, n=1,997
was commercially licensed, giving patients the opportunity to be
tinuations and completions are listed for the entire duration of the
Arthritis phase 3b study; ReAlise, the Registry of HUMIRA™ in RA: a
y.
Table 1 Baseline demographics and disease activity
At baseline in ReAct At baseline in ReAlise
Parameter n Value n Value
Age, y, mean (SD) 6,610 53.7 (13.0) 3,435 54.5 (12.5)
Female, n (%) 6,610 5,332 (80.7) 3,435 2,724 (79.3)
Duration of RA, y, mean (SD) 6,572 10.8 (8.6) 3,423 12.0 (8.6)
Rheumatoid factor positive, n (%) 6,610 4,811 (72.8) 3,429 2,548 (74.2)*
DMARD use at baseline, n (%) 6,610 4,879 (73.8) 3,435 2,636 (76.7)*
SJC (28), mean (SD) 6,607 10.4 (5.8) 3,435 2.2 (3.4)
TJC (28), mean (SD) 6,607 13.5 (7.0) 3,435 3.2 (4.7)
PtGA, mm VAS, mean (SD) 6,568 61.9 (21.4) 3,256 26.2 (23.3)
DAS28 (ESR), mean (SD) 6,554 6.0 (1.1) 2,729 3.5 (1.3)
HAQ DI, mean (SD) 6,560 1.64 (0.68) 3,235 0.89 (0.74)
CRP, mg/L, mean (SD) 6,535 25.7 (30.8) 2,962 9.5 (15.7)
*At time of entry into ReAct study. CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte
sedimentation rate; HAQ DI, Health Assessment Questionnaire Disability Index; PtGA, patient global assessment; RA, rheumatoid arthritis; SD, standard deviation;
SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.
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(2.5) and 1.5 years, representing 18,272 PYs of exposure.
The mean (SD) and median intervals between comple-
tion of ReAct and enrolment in ReAlise were 5.5 (3.4)
and 4.8 months, respectively.
Safety
Overall, 81.8% of patients experienced one or more
treatment-emergent AEs at any time from the first injec-
tion in ReAct to the end of ReAlise, with an overall AETable 2 Overview of serious adverse events and adverse even
ADA treatment
Adverse event (AE)
Overall
N = 6,610
(18,272 PYs)
Tim
≤0.5 Y >
N = 6,610 N
(3,059 PYs) (2
Serious AEs* 2,529 (13.8) 838 (27.4)
Fatal AEs 102 (0.6) 29 (0.9)
Serious infections* 518 (2.8) 162 (5.3)
TB† 35 (0.2) 11 (0.4)
Sepsis 35 (0.2) 13 (0.4)
Malignancies‡ 121 (0.7) 19 (0.6)
Lymphoma 15 (0.1) 1 (<0.1)
NMSC 43 (0.2) 8 (0.3)
Serious CHF* 47 (0.3) 15 (0.5)
Cerebrovascular AEs§ 56 (0.3) 13 (0.4)
Serious hepatic events* 58 (0.3) 10 (0.3)
*Serious adverse events include those that met any of the following criteria: death,
medical intervention), hospitalisation, prolongation of hospitalisation, and persisten
surgical intervention to prevent serious outcome. †Including two patients with a po
These 121 events occurred in 114 subjects. §Such as stroke and transient ischemic a
non-melanoma skin cancer; PYs, patient-years; TB, tuberculosis.incidence rate of 137.7 E/100 PYs. The overall incidence
rate of serious adverse events (SAEs) was 13.8 E/100 PYs
(Table 2), with SAEs reported more frequently during the
first 6 months of treatment and decreasing thereafter. The
overall incidence rate of serious infections was 2.8 E/100
PYs, and this rate also decreased over time. Regarding AEs
of special interest in RA, rates of tuberculosis (TB), malig-
nancies, lymphoma, non-melanoma skin cancer (NMSC),
serious congestive heart failure, cerebrovascular events
and serious hepatic events decreased over the period fromts of interest (E (E/100 PYs)) during more than 5 years of
e windows after the first injection of ADA in ReAct
0.5 to 1 Y >1 to 3 Y >3 to 5 Y >5 Y
= 5,922 N = 4,283 N = 2,623 N = 2,000
,256 PYs) (6,149 PYs) (4,549 PYs) (2,260 PYs)
419 (18.6) 661 (10.7) 417 (9.2) 194 (8.6)
19 (0.8) 27 (0.4) 17 (0.4) 10 (0.4)
83 (3.7) 154 (2.5) 81 (1.8) 38 (1.7)
11 (0.5) 8 (0.1) 4 (0.1) 1 (<0.1)
4 (0.2) 7 (0.1) 7 (0.2) 4 (0.2)
16 (0.7) 45 (0.7) 25 (0.5) 16 (0.7)
0 9 (0.1) 4 (0.1) 1 (<0.1)
2 (0.1) 17 (0.3) 11 (0.2) 5 (0.2)
6 (0.3) 12 (0.2) 13 (0.3) 1 (<0.1)
5 (0.2) 16 (0.3) 15 (0.3) 7 (0.3)
13 (0.6) 16 (0.3) 13 (0.3) 6 (0.3)
life-threatening (that is, would have resulted in immediate fatality without
t or significant disability, or any important medical event requiring medical or
sitive test for latent TB during ADA therapy. ‡Excluding, lymphomas and NMSC.
ttack. ADA, adalimumab; CHF, congestive heart failure; E, events; NMSC,
Figure 2 Percentages of patients with (A) American College
of Rheumatology (ACR) 20%, 50%, or 70% improvement;
(B) European League Against Rheumatism (EULAR) responses
of at least ‘moderate’ and ‘good’; and (C) low disease activity
(LDA) and disease remission (REM) defined as Simplified
Disease Activity Index (SDAI) ≤11 and SDAI ≤3.3, respectively.
Data are shown as observed values for all evaluable patients at each
time point during long-term treatment with adalimumab (ADA).
LO, last observation.
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of TB, 16 (45.7%) were extra-pulmonary.
SIR was 0.64 (95% confidence interval (CI) 0.53 to
0.76) for all malignancies (118 observeda/185.48 ex-
pected), excluding NMSC, and 1.99 (95% CI 1.11 to
3.28) for lymphomas (15 observed/7.55 expected). SIR
for melanoma was 1.29 (95% CI 0.59 to 2.54; 8 ob-
served/6.20 expected). Overall SMR was 0.71 (95% CI
0.57 to 0.87); there were fewer observed deaths during
ADA exposure (90) than expected (127). The SMR was
0.60 (95% CI 0.38 to 0.89) for men and 0.76 (95% CI
0.59 to 0.96) for women. For both men and women,
fewer deaths were observed (23 and 67, respectively)
than were expected (39 and 88, respectively).
Subgroup safety analyses
The incidences of SAEs were slightly higher among
patients who received ADA monotherapy (no DMARDs)
and those who received corticosteroids (17.4 and 14.9
E/100 PYs, respectively) than for those who received at
least one concomitant DMARD and those who did not
receive corticosteroids (12.8 and 11.5 E/100 PYs, re-
spectively). The rates of serious infections were generally
similar. For patients who had received prior TNF antag-
onists, the overall incidence of serious infections was
higher (4.2 E/100 PYs) than that for patients who had
not received prior TNF antagonists (2.7 E/100 PYs). All
other AEs of interest, including malignancies and lymph-
omas, were reported at similar rates for patients with
and without a history of exposure to TNF antagonists at
study entry. Similar to the overall population, SAEs and
AEs of interest occurred more frequently during the ini-
tial 6 months of therapy and decreased thereafter in all
subgroups (see Tables S1-S6 in Additional file 3 for
data).
Effectiveness
Over more than 5 years of ADA treatment, ACR and
EULAR categorical responses were maintained (Figure 2A
and 2B). At last observation, ACR20, ACR50 and ACR70
responses were achieved by 66%, 45% and 28%, respect-
ively, and moderate and good EULAR responses were
achieved by 80% and 42%, respectively. The percentages of
patients achieving the stringent ACR/EULAR index-based
definitions of LDA and REM based on SDAI were sus-
tained over the course of the study, with 50% achieving
LDA at last observation (Figure 2C). Approximately one
in five patients achieved REM at last observation, while
more than one-third of patients who completed 5 years of
ADA achieved REM.
Mean DAS28 (ESR) scores and individual component
values showed consistent improvements throughout treat-
ment with ADA (Table 3). Reductions in mean HAQ DI
score were observed at 0.5 years and remained stable
Table 3 DAS28 (ESR) composite and individual component values, and SDAI and HAQ DI scores at 0.5, 1, 3 and 5 years
of ADA exposure and last observation
Parameter 0.5 Y 1 Y 3 Y 5 Y LO
DAS28 (ESR)
Mean (SD) 3.6 (1.5) 3.4 (1.4) 3.1 (1.3) 2.9 (1.2) 3.8 (1.6)
Median (IQR) 3.5 (2.0) 3.3 (2.0) 2.9 (1.8) 2.8 (1.5) 3.6 (2.4)
PtGA, mm VAS
Mean (SD) 30.6 (24.6) 27.8 (23.7) 25.1 (22.9) 23.4 (21.6) 34.5 (27.1)
Median (IQR) 25.0 (37.0) 22.0 (35.0) 19.0 (32.0) 18.0 (30.3) 30.0 (44.0)
TJC (28)
Mean (SD) 4.1 (5.4) 3.2 (4.6) 2.4 (4.1) 1.9 (3.6) 4.6 (6.3)
Median (IQR) 2.0 (6.0) 2.0 (4.0) 1.0 (3.0) 0.0 (2.0) 2.0 (6.0)
SJC (28)
Mean (SD) 3.0 (4.1) 2.3 (3.5) 1.4 (2.8) 1.1 (2.5) 3.1 (4.6)
Median (IQR) 2.0 (4.0) 1.0 (3.0) 0.0 (2.0) 0.0 (1.0) 1.0 (4.5)
ESR, mm/h
Mean (SD) 24.1 (20.0) 23.1 (19.3) 21.7 (17.5) 21.3 (17.3) 26.9 (22.2)
Median (IQR) 18.0 (22.0) 18.0 (20.0) 17.0 (21.0) 17.0 (19.0) 20.0 (27.0)
SDAI
Mean (SD) 13.7 (12.1) 11.4 (10.6) 8.8 (9.0) 7.6 (8.2) 14.7 (14.2)
Median (IQR) 10.3 (13.5) 8.5 (11.9) 6.1 (9.3) 5.2 (8.0) 10.1 (16.8)
HAQ DI score
Mean (SD) 1.01 (0.78) 0.94 (0.76) 0.85 (0.73) 0.80 (0.72) 1.09 (0.82)
Median (IQR) 1.00 (1.3) 0.88 (1.3) 0.75 (1.1) 0.63 (1.1) 1.00 (1.4)
ADA, adalimumab; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ DI, Health Assessment Questionnaire Disability Index; IQR,
interquartile range; LO, last observation; PtGA, patient global assessment; SD, standard deviation; SDAI, Simplified Disease Activity Index; SJC, swollen joint count;
TJC, tender joint count; VAS, visual analogue scale.
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(Table 3). The proportion of patients who achieved clinic-
ally relevant reductions in physical disability at last obser-
vation was 68% and showed consistency over 5 years,
ranging from 72 to 80% (Figure 3A). The proportion of
patients with normal function (HAQ DI ≤0.5) was 32% at
last observation and ranged from 35 to 45% over 5 years
of ADA treatment (Figure 3B). For those patients who had
achieved either sustained LDA (SDAI ≤11) or sustained
REM (SDAI ≤3.3) for at least 6 months, there was a
greater reduction in mean HAQ DI than for those patients
without sustained LDA or REM (Figure 4).
For patients who had received prior TNF antagonists
(infliximab or etanercept), both the ACR and EULAR re-
sponses were slightly lower than those patients who had
not received prior TNF antagonists (Figure S1 in Additional
file 4 and Figure S2 in Additional file 5). At last observation
the ACR20, ACR50, and ACR70 responses were achieved
by 68%, 47%, and 29% in those without prior TNF antago-
nists and 55%, 32%, and 17% in the patients who had re-
ceived prior TNF antagonists. The percentages of patients
achieving the stringent ACR/EULAR index-based defini-
tions of LDA and REM based on SDAI were also slightlyless for the patients who had previous TNF antagonists
(Figure S3 in Additional file 6). Additionally, the proportion
of patients with normal function (HAQ DI ≤0.5) was 34%
at last observation for those without prior TNF antagonists
and 19% in the patients who had received prior TNF
antagonists.
Discussion
The combined data from ReAct and ReAlise include
more than 6,600 RA patients and provide one of the lar-
gest well-monitored evaluations of the long-term safety
and effectiveness of a single TNF antagonist in routine
clinical practice settings. Other reports involving thou-
sands of RA patients come from country registries that
record and compare use of multiple TNF antagonists
[18-22]. The observational study design allows for inclu-
sion of patients receiving routine care for RA and is not
restricted to patients who meet the stricter entry criteria
of randomised controlled trials, including fewer comor-
bidities. Patients enrolled in ReAct and ReAlise reflect
typical RA patients treated with TNF antagonists, who
have long-standing RA with moderate to severe baseline
disease activity despite treatment with DMARDs. Some
Figure 3 Percentages of patients with (A) minimal important
difference ≥0.22 on the Health Assessment Questionnaire
Disability Index (HAQ DI) and (B) normal function defined as
HAQ DI ≤0.5 over long-term adalimumab (ADA) treatment.
Observed data are reported. LO, last observation.
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etanercept.
ADA was well tolerated, and no new or unexpected
safety concerns were identified during more than 5 years
of therapy, representing nearly 20,000 PYs. The pattern
and rates of AEs were comparable with those observed
in double-blind studies of ADA with or without metho-
trexate [2,3,7]. SAEs, including serious infections and
TB, were reported more frequently during the first year,
after which the incidences decreased and remained
stable. This finding is expected because of positive selec-
tion bias of the patients who tolerate the drug and less
frequent visits in ReAlise, and generally aligns with data
from ADA clinical trials and registries [4,7,18,23-25]. A
recent review of safety data from ADA clinical studies
across indications found a stable rate of serious infec-
tions throughout ADA exposure, which may be attrib-
uted to differences in populations and methodology [26].
Beyond the positive selection bias of the patients who
tolerate the drug, the other possible explanations for the
decrease in infection risk with ongoing TNF antagonist
therapy may include decreased use of corticosteroids
and better control of the RA disease process that reducesdisease-associated alterations in natural immunity [18,19].
The overall incidence rates of SAEs and serious infections
with ADA (13.8 and 2.8 E/100 PYs) were found to be
within the range of those previously reported in long-term
clinical trials of other TNF antagonists and biological
DMARDs. Rates of serious infections for infliximab and
etanercept after a median follow-up of 3.9 years in the
British registry were 4.6 and 3.8 E/100 PYs, respectively
[18]. Five-year data on abatacept and tocilizumab report
serious infection rates of 3.0 and 5.7 E/100 PYs, respect-
ively [27,28]. SAEs of interest other than serious infections
occurred at a low frequency and decreased over time with
ADA. Similarly, the risk of TB decreased over time, with
an incidence rate <0.1% in the patients treated more than
5 years. Still, five cases occurred in patients treated for
more than 3 years, underscoring the need for continued
attention to the risk of infection. There was no overall in-
creased risk of malignancies; however, use of a US data-
base (NCI) as a comparator for SIRs in this largely
European population may limit interpretation of results.
The observed risk of lymphomas was consistent with that
for RA patients. The risk of lymphoma, both Hodgkin’s
and non-Hodgkin’s, is increased by approximately two-
fold in patients with RA, and this increase has been associ-
ated with the chronic inflammation of RA [23,29,30]. Use
of disease-modifying treatment that controls chronic in-
flammation may reduce the elevated risk associated with
uncontrolled RA. Recent long-term studies have failed to
identify an effect of TNF antagonists on the incidence of
cancer, including lymphoma (with exception of NMSC),
and also determined that the relative risk of cancer did
not increase with time since first starting a TNF antagonist
or with cumulative duration of TNF antagonist therapy
[31-33]. Lastly, mortality rates were lower in patients re-
ceiving ADA therapy in ReAct and ReAlise than observed
in a matched population without RA, and there was no in-
crease in the overall mortality rate over the course of the
studies. The decreased rates of cancer and mortality must
be interpreted with caution because patients with previous
cancers may have been excluded from receiving a TNF
antagonist.
Patients were allowed to continue concomitant DMARD
therapy and/or corticosteroids with ADA in ReAct and
ReAlise. Generally, the incidences of SAEs were similar
among subgroups based on concomitant therapy, with a
slightly higher rate among patients who received ADA
monotherapy (no DMARDs) and those who received cor-
ticosteroids (17.4 and 14.9 E/100 PYs, respectively). Pa-
tients who had received etanercept and/or infliximab
before enrolling in ReAct showed a higher rate of SAEs
and infections than patients without prior history of TNF
antagonist therapy, but no differences in the rates of
malignancies or lymphoma were observed. Statistical
analyses of these subgroups were not performed in this
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Figure 4 Mean change of Health Assessment Questionnaire Disability Index (HAQ DI) from baseline in patients (A) with sustained low
disease activity (LDA) defined as Simplified Disease Activity Index (SDAI) ≤ 11 for at least 6 months and without sustained LDA and
(B) with sustained remission (REM) defined as SDAI ≤ 3.3 for at least 6 months and without sustained REM. Data are shown as observed
values for all evaluable patients at each time point during long-term treatment with adalimumab (ADA). *Denotes significance from baseline,
P ≤0.001. LO, last observation.
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have been identified in controlled clinical studies that
evaluated AEs in subgroups based on prior or concomi-
tant treatment [2,3,12].
The effectiveness of ADA in reducing disease activity
and inflammation was maintained over more than 5
years of treatment, as evidenced by the percentages of
patients achieving ACR20, 50 and 70 responses and at
least moderate EULAR responses. The initial 12-week
improvements observed in ReAct included ACR20 in
69% and moderate and good EULAR responses in 83%
and 33%, respectively [11]. For patients who continued
in ReAlise, these response rates were 66%, 80% and 42%,
respectively, at last observation. LDA and REM rates
also were maintained at last observation, with half of the
patients achieving LDA, and one in five achieving REM.
Clinically relevant functional improvement was reported
for approximately two-thirds of patients, and one-third
of patients reported normal function at last observation.
Approximately 70% of patients who received prior
TNF antagonists discontinued that therapy because ofloss or lack of response before enrolling in ReAct/ReAl-
ise. At week 12 of ReAct, substantial clinical benefit was
achieved with ADA in patients previously treated with
infliximab and/or etanercept [12], and response rates
were maintained through 3 years of ADA [34]. In agree-
ment with our data, clinical studies that have evaluated
the effectiveness of switching TNF antagonists have gen-
erally found that treatment with a second TNF antagon-
ist can offer comparable or slightly lower response rates
than those observed in TNF antagonist-naive patients
[20,35,36]. However, as the number of TNF antagonists
increase to three or more, response rates decrease. In a
study of more than 2,000 RA patients, discontinuation
rates were similar for infliximab, etanercept and ADA,
and factors predictive of discontinuation were increased
disease severity and comorbidities [36]. Delaying ad-
ministration of TNF antagonists in patients who fail to
achieve an adequate response with methotrexate has
been associated with poorer clinical, functional and
radiographic outcomes [4,37]. The findings from ReAct/
ReAlise indicate that switching from failed therapy with
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without concomitant DMARD) is a reasonable strategy.
Limitations of long-term observational studies include
inherent bias. Patients who experience effective or toler-
able therapy are likely to continue treatment. In ReAct/
ReAlise, the most common reasons for patients discon-
tinuing the study were loss of efficacy and AEs. To address
potential bias, assessment of effectiveness over 5 years in-
cluded results for all efficacy parameters at last observa-
tion. Results at last observation were consistent with
results at the end of 12-week treatment in ReAct [11].Conclusions
In a clinical practice setting, ADA was well tolerated, and
no new safety concerns were identified during nearly
20,000 PYs of exposure. The incidence of SAEs and ser-
ious infections decreased with ongoing ADA treatment
over 5 years. The incidences of deaths and malignancies
were lower than expected for the general population, and
the incidence of lymphoma was within expected rates for
patients with RA. Clinical response to ADA, as measured
by reduced disease activity and functional improvements,
was maintained through more than 5 years of observation
in patients with long-standing, severe RA. Safety and ef-
fectiveness observed in more than 6,600 RA patients over
5 years were consistent with results of randomised clinical
trials of ADA [2,3,7].Endnotes
aFrom a total of 129 cases (114 cases of malignancy
(excluding lymphomas, and NMSC) plus 15 cases of
lymphoma), 11 were excluded (9 cases of carcinoma in
situ and 2 of metastases for which the primary cancer
was already counted), in keeping with the SEER database
criteria for comparison.Additional files
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